Table 2.

Treatment review of PGNMID in renal allograft

	Number of patients	Patient	De novo versus recurrent disease	Cr (mg/dL) upon presentation	Treatment	Cr (mg/dL) after treatment
		1	Recurrent	2.8	Steroids, PO cytoxan for 6 months	2.3
Nasr et al. [3]	4	2	Recurrent	3.7	Steroids for 8 months, rituximab × 2, lisinopril for 6 months	1.1
		3	Recurrent	4.8	Steroids, rituximab × 1, PLX × 4, and HD × 3	1.3
		4	Recurrent	1.2	Steroids for ACR, rituximab × 2	2.3
		1	Recurrent	2.7	No change in immunosuppression	1.7–2.5; patient died from fatal myocardial infarct
Albawardi et al. [12]	4	2	Recurrent	3.9	Adjusted immunosuppression from MFA and sirolimus to MFA and steroids	3.3; patient died from fatal cryptococcal meningitis
		3	De novo	2.6	Prednisone and cyclosporine	ESRD
		4	De novo	2.8	No mention	No mention
Rhangino et al. [8]	1	1	Recurrent	2.0	PLX, IVIG, steroids	1.1
Al-Rabadi [11]	3	1	De novo	1.2	Bortezomib and dexamethasone × 3 doses, then switched to carfilzomib	1.70
		2	Recurrent	4.48	Patient opted for no treatment	ESRD
		3	De novo	1.0	No change in immunosuppression: tacrolimus and azathioprine	1.28

ACR, acute cellular rejection; HD, hemodialysis; IVIG, intravenous immunoglobulin; MFA, mycophenolic acid; PLX, plasmapharesis; PO, oral.